GIVES YOUR EYES A BETTER PERSPECTIVE
MACUPREV® is the only product, with documented efficacy, that can increase macular cell function.
ACTS ON CHRONIC INFLAMMATION, WHICH IS CONSIDERED ONE OF THE CONCOMITANT CAUSES OF WORSENING DMLE OR AMD, AND ON THE "COMPLEMENT" FACTOR THAT PLAYS A KEY ROLE IN THE CHRONIFICATION OF INFLAMMATION ITSELF.
To evaluate the effectiveness of Macuprev in
improving the function of the
ganglion cells, a study was conducted in a
double-blind, single-center randomized
and prospective, on thirty patients
(mean age 68 +/- 9.3 years) with
ADM intermediate.
The patients were divided into two groups
similar in age: 15 patients (AMD-M group)
received for 6 months, a supplementation
daily oral supplementation of two tablets of
Macuprev on an empty stomach, before
meals, and 15 patients (AMD-P group)
received for 6 months two tablets of
placebo on an empty stomach, before
meals.
All patients were evaluated
with multifocal electroretinogram
(mfERG) and SD-OCT before the start of the
treatment and after 6 months after the same.
The results show that after 6 months
after treatment, patients in the
ADM-M achieved a significant
increase in the magnitude of the response
to mfERG recorded in the macular areas
central even in the absence of changes
structural changes evident by SD-OCT.
No functional nor structural
changes were found in patients
ADM-P group.
improving the function of the
ganglion cells, a study was conducted in a
double-blind, single-center randomized
and prospective, on thirty patients
(mean age 68 +/- 9.3 years) with
ADM intermediate.
The patients were divided into two groups
similar in age: 15 patients (AMD-M group)
received for 6 months, a supplementation
daily oral supplementation of two tablets of
Macuprev on an empty stomach, before
meals, and 15 patients (AMD-P group)
received for 6 months two tablets of
placebo on an empty stomach, before
meals.
All patients were evaluated
with multifocal electroretinogram
(mfERG) and SD-OCT before the start of the
treatment and after 6 months after the same.
The results show that after 6 months
after treatment, patients in the
ADM-M achieved a significant
increase in the magnitude of the response
to mfERG recorded in the macular areas
central even in the absence of changes
structural changes evident by SD-OCT.
No functional nor structural
changes were found in patients
ADM-P group.
OTHER PRODUCTS IN THE OFTA LINE
